Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
SENL-101 by Hebei Senlang Biotechnology for Refractory Acute Myeloid Leukemia: Likelihood of Approval
SENL-101 is under clinical development by Hebei Senlang Biotechnology and currently in Phase I for Refractory Acute Myeloid Leukemia. According...
Data Insights
SENL-101 by Hebei Senlang Biotechnology for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
SENL-101 is under clinical development by Hebei Senlang Biotechnology and currently in Phase I for Relapsed Acute Myeloid Leukemia. According...